- Trial phase
- Phase 3 (completed)
- Time to market
- BLA submission planned by end of 2026; regulatory approval targeted for 2027 if the FDA accepts and reviews the application on a standard timeline.
- Why 6/10
- The next hard catalyst is the planned BLA submission for intismeran in melanoma by end of 2026 (about 1-2 months away), as stated on Moderna's Q3 2026 earnings call. This is a milestone event but not a binary regulatory decision; the actual PDUFA approval decision would follow in 2027. The drug is a major pipeline value driver for Moderna, but Moderna also has approved COVID and RSV products, so the company is not a single-asset binary.
Watch for Moderna's BLA submission for intismeran in melanoma by end of 2026. A submission would confirm the regulatory path is on track, while any delay would be a negative signal. The actual PDUFA decision (likely in 2027) is the true binary catalyst. The stock has already rallied ~978% over the past year, and the mean analyst price target of $145 implies ~42% downside from the current ~$259, suggesting much of the good news may already be priced in.
Price Chart
Executive Summary
Intismeran (also known as intismeran autogene, V940, or mRNA-4157) is a personalized mRNA cancer therapy co-developed by Moderna (MRNA) and Merck (MRK). In October 2026, the Phase 3 INTerpath-001 trial met its primary endpoint: intismeran plus Keytruda reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone in patients with resected high-risk melanoma. Detailed results were presented at the ESMO 2026 Presidential Symposium. Moderna management stated on the Q3 2026 earnings call that it plans to submit a Biologics License Application (BLA) by end of 2026, targeting regulatory approval in 2027. The stock has already rallied ~978% over the past year, and the mean analyst price target of ~$145 implies significant downside from the current ~$259 price, suggesting much of the optimism may already be priced in.
How It Works
Intismeran is a personalized mRNA cancer therapy. Doctors first sequence a patient's tumor to find its unique genetic mutations (neoantigens). Then a custom mRNA vaccine is manufactured that teaches the patient's immune system to recognize and attack cells carrying those specific mutations. It is designed to be used in combination with Merck's immunotherapy Keytruda (pembrolizumab), which takes the brakes off the immune system, so the two drugs work together: the vaccine tells immune cells what to target, and Keytruda keeps those cells active.
Trial Status
The pivotal Phase 3 INTerpath-001 trial in resected stage IIB-IV melanoma met its primary endpoint (recurrence-free survival) and key secondary endpoint (distant metastasis-free survival). Detailed results were presented at ESMO 2026 in October. A separate Phase 3 trial in cutaneous squamous cell carcinoma (V940-007, NCT06295809) was terminated. The companies have also demonstrated successful large-scale manufacturing, serving 99% of trial patients with personalized vaccines.
The Two-Sided Case
Upcoming Catalysts
- BLA submission to FDA by end of 2026 (targeted per Moderna Q3 2026 earnings call)
- Potential FDA acceptance and PDUFA date assignment in 2027
- Potential regulatory decisions in other markets (EU, etc.)
- Possible expansion into other cancer indications beyond melanoma
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Moderna, Inc. 8-K MRNA ·Originating report